COMP <GO>
PCVX vs KRYS // DIVIDEND YIELD & FCF PAYOUT SAFETY
Vaxcyte Inc. (NASDAQ) VS. Krystal Biotech Inc. (NASDAQ) • 15-METRIC TALLY: PCVX 4
— KRYS 7
■ METRIC PARITY
LAST: $62.61 (+1.87%) • MKT CAP: $9.85B
dividend-safety
0.00%
LAST: $324.55 (+0.97%) • MKT CAP: $9.61B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PCVX VS. KRYS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PCVX | KRYS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.60% | 16.50% | -44.10 | KRYS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 53.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.79% | 1.97% | -8.76 | KRYS | /fcf-yield <GO> |
| Operating Margin | -33.50% | 41.50% | -75.00 | KRYS | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 52.60% | -52.60 | KRYS | /net-margins <GO> |
| Revenue Growth (YoY) | 19.80% | 33.90% | -14.10 | KRYS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 18.11 | 26.00 | -7.89 | KRYS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | KRYS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.1 | 48.2 | +1.90 | PCVX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.91 | +0.16 | PCVX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 39.4x | -16.40 | PCVX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.85B | $9.61B | $247.9M | PCVX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PCVX REV | KRYS REV | PCVX GROSS % | KRYS GROSS % | PCVX FCF | KRYS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $389.1M | — | — | -$669.3M | $188.9M |
| FY 2024 | $0 | $290.5M | — | — | -$475.1M | $119.2M |
| FY 2023 | $0 | $50.7M | — | — | -$296.8M | -$91.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PCVX // BETA 1.07
KRYS // BETA 0.91